Gonzalez Jeffrey S, Kane Naomi S, Binko Deborah H, Shapira Amit, Hoogendoorn Claire J
Ferkauf Graduate School of Psychology, Yeshiva University, Bronx, NY
Departments of Medicine (Endocrinology) and Epidemiology & Population Health, Albert Einstein College of Medicine, Bronx, NY.
Diabetes Care. 2016 Dec;39(12):2182-2189. doi: 10.2337/dc16-1657. Epub 2016 Oct 17.
OBJECTIVE: We conducted comprehensive assessments of emotional distress to examine relations with diabetes medication adherence over time. RESEARCH DESIGN AND METHODS: Ethnically and socioeconomically diverse adults treated for type 2 diabetes completed validated self-reports (SRs) for diabetes distress and depression, were administered semistructured depression interviews, and provided blood samples for A1C. Medication adherence among 104 participants was electronically monitored (EM) over the subsequent 3 months; validated SRs of medication adherence were also obtained. Hierarchical linear regression evaluated independent effects of diabetes distress and depression on adherence. RESULTS: Mean ± SD 3-month medication adherence was 76.1% ± 25.7% for EM and 83.7% ± 21.9% for SR. Higher levels of SR (P < 0.001) and interview-based (P < 0.05) depressive symptom severity (P < 0.05) and diabetes-related distress (P < 0.01) showed a significant bivariate association with EM and SR nonadherence. Regression models showed baseline diabetes distress was a significant independent predictor of EM (β = -0.29; P = 0.001) and SR adherence (β = -0.24; P < 0.02) at follow-up. SR depression was an independent predictor of EM and SR adherence and reduced the effects of diabetes distress to nonsignificance. Subsequent models indicated this effect was driven by somatic rather than cognitive-affective symptoms of depression. Results were consistent but weaker for interview-based depressive symptoms. CONCLUSIONS: Findings support diabetes-related distress and depression symptom severity as risk factors for type 2 diabetes medication nonadherence. Somatic symptoms captured by depression measures, but not cognitive-affective symptoms, independently predict nonadherence and should be further investigated as a potential link between emotional distress and nonadherence.
目的:我们对情绪困扰进行了全面评估,以研究其与糖尿病药物治疗依从性随时间的关系。 研究设计与方法:接受2型糖尿病治疗的不同种族和社会经济背景的成年人完成了关于糖尿病困扰和抑郁的有效自评报告(SR),接受了半结构化抑郁访谈,并提供了糖化血红蛋白(A1C)的血样。在随后的3个月内,对104名参与者的药物治疗依从性进行了电子监测(EM);同时也获得了关于药物治疗依从性的有效自评报告。分层线性回归评估了糖尿病困扰和抑郁对依从性的独立影响。 结果:电子监测的3个月药物治疗依从性平均±标准差为76.1%±25.7%,自评报告的为83.7%±21.9%。自评报告中较高水平(P<0.001)、基于访谈的抑郁症状严重程度(P<0.05)以及与糖尿病相关的困扰(P<0.01)与电子监测和自评报告的不依从性呈显著的双变量关联。回归模型显示,基线糖尿病困扰是随访时电子监测依从性(β=-0.29;P=0.001)和自评报告依从性(β=-0.24;P<0.02)的显著独立预测因素。自评报告的抑郁是电子监测和自评报告依从性的独立预测因素,并使糖尿病困扰的影响降至不显著水平。后续模型表明,这种效应是由抑郁的躯体症状而非认知情感症状驱动的。基于访谈的抑郁症状结果一致但较弱。 结论:研究结果支持将与糖尿病相关的困扰和抑郁症状严重程度作为2型糖尿病药物治疗不依从的危险因素。抑郁测量所捕捉到的躯体症状而非认知情感症状可独立预测不依从性,应作为情绪困扰与不依从性之间的潜在联系进一步研究。
Can J Diabetes. 2017-4-24
J Diabetes Complications. 2018-12-7
Clin Cosmet Investig Dermatol. 2025-6-30
Transl Psychiatry. 2025-1-24
World J Diabetes. 2024-7-15
Stigma Health. 2024-2
Lancet Diabetes Endocrinol. 2015-5-17
Ann Behav Med. 2014-10